Meridian Biosciences (VIVO -5%) slides after reporting a mixed FQ2 this morning, with its EPS coming in at $0.24, in line with the Street, but revenue came in at $47.3M versus the estimated $49.66M. Sales were flat year over year. USDx sales increased by 7%, driven primarily by increases in C. difficile and foodborne test revenues. EURDx business unit sales -12%, due largely to continued weakness in European healthcare spending. Meridian Life Science revenue -8%.
Meridian Bioscience (VIVO -1.4%) says it's successfully completed beta trials for two new illumigene molecular amplification tests. The assays are designed to specifically detect the DNA of Chlamydia trachomatis and Neisseria gonorrhoeae from both swab and urine samples.